Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort MOVEMENT DISORDERS Simuni, T., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., Jennings, D., Tanner, C. M., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Schuff, N., Singleton, A., Kieburtz, K., Toga, A. W., Mollenhauer, B., Galasko, D., Chahine, L. M., Weintraub, D., Foroud, T., Tosun, D., Poston, K., Arnedo, V., Frasier, M., Sherer, T., Chowdhury, S., Marek, K., Parkinson's Progression Marker Ini 2018; 33 (5): 771–82

Abstract

The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD.We describe 5-year longitudinal change of the MDS-UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123-I Ioflupane striatal binding and correlation between the 2 measures.A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS-UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P?

View details for PubMedID 29572948

View details for PubMedCentralID PMC6001458